Translate Bio Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Translate Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBIO, but not buy additional shares or sell existing shares.
View analyst ratings for Translate Bio or view top-rated stocks.

Wall Street analysts have given Translate Bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Translate Bio saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,290,000 shares, an increase of 43.5% from the August 15th total of 2,990,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is presently 1.6 days. Approximately 6.4% of the shares of the stock are sold short.
View Translate Bio's Short Interest.

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Translate Bio.

Translate Bio, Inc. (NASDAQ:TBIO) released its earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.44. The business had revenue of $72.65 million for the quarter, compared to the consensus estimate of $38.23 million. Translate Bio had a trailing twelve-month return on equity of 1.50% and a net margin of 17.97%.
View Translate Bio's earnings history.

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TBIO shares have increased by 402.8% and is now trading at $37.36.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued twelve-month target prices for Translate Bio's shares. Their forecasts range from $19.00 to $38.00. On average, they anticipate Translate Bio's share price to reach $26.29 in the next year. This suggests that the stock has a possible downside of 29.6%.
View analysts' price targets for Translate Bio or view top-rated stocks among Wall Street analysts.

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Translate Bio include Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Adagio Therapeutics (ADGI), Abcam (ABCM) and Sana Biotechnology (SANA).
View all of TBIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Translate Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.15%), BlackRock Inc. (7.38%), Vanguard Group Inc. (5.08%), Federated Hermes Inc. (4.95%), State Street Corp (4.54%) and Frazier Management LLC (2.77%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire, Jean Francois Formela, Owen Hughes, Paul D Burgess, Ronald C Renaud, Jr and Sanofi.
View institutional ownership trends for Translate Bio.

TBIO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Goldman Sachs Group Inc., Ikarian Capital LLC, Millennium Management LLC, Nuveen Asset Management LLC, First Trust Advisors LP, BlackRock Inc., and Allianz Asset Management GmbH. Company insiders that have sold Translate Bio company stock in the last year include Jean Francois Formela, Owen Hughes, Paul D Burgess, and Ronald C Renaud, Jr.
View insider buying and selling activity for Translate Bio or view top insider-selling stocks.

TBIO stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Senvest Management LLC, Vanguard Group Inc., State Street Corp, and Marshall Wace LLP. Company insiders that have bought Translate Bio stock in the last two years include Baupost Group Llc/Ma, and Sanofi.
View insider buying and selling activity for Translate Bio or or view top insider-buying stocks.

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBIO stock can currently be purchased for approximately $37.36.

Translate Bio has a market capitalization of $2.82 billion and generates $138.81 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

Translate Bio employs 122 workers across the globe.

The official website for Translate Bio is www.translate.bio.

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at (203) 787-7888.